Join ERA4H webinar to explore GLP-1 mechanisms in reducing cardiovascular disease and comorbidities, delivered by Dr. Daniel J. Drucker (UofT). This session pre-announces ERA4Health’s 6th Joint Transnational Call (JTC) "InterHeart," fostering European collaborative research on cardiovascular disease and therapeutic interactions.

Join ERA4Health for an insightful webinar featuring Dr. Daniel J. Drucker, Senior Investigator at Mt. Sinai Hospital and Professor of Medicine at the University of Toronto, as he delves into the mechanisms by which GLP-1 (Glucagon-like peptide-1) contributes to reducing cardiovascular disease and associated comorbidities.

GLP-1, a hormone involved in glucose regulation and appetite control, has shown promising cardiovascular benefits, including improved endothelial function, reduced inflammation, and modulation of lipid profiles. Dr. Drucker will explore how these mechanisms intersect to mitigate cardiovascular risks and enhance therapeutic outcomes for patients with comorbid conditions.

This session will also pre-announce ERA4Healths 6th Joint Transnational Call (JTC), titled: Understanding the Interactions Between Cardiovascular Diseases and Comorbidities and/or Their Therapeutic Treatments. This call, under the InterHeart initiative, aims to foster European collaborative research and advance innovative solutions for cardiovascular health.

Details : 
When : January 29, 14:00 - 15:00 CET
Registration is required : follow this link